Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclacillin is a semisynthetic aminopenicillin antibiotic and a cyclohexylamido analog of penicillanic acid. It was developed as an orally active penicillin with improved absorption and greater resistance to beta-lactamase hydrolysis compared to ampicillin. Its primary mechanism of action is the inhibition of bacterial cell wall synthesis through binding to penicillin-binding protein (PBP), resulting in bactericidal activity. Cyclacillin was used for the treatment of bacterial infections caused by susceptible organisms, including both gram-positive and some gram-negative bacteria. It has largely been replaced by newer penicillins due to advances in antibiotic therapy[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclacillin.